These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28783374)

  • 1. HIV and Cognitive Impairment in Clinical Practice: The Evaluation of a Stepwise Screening Protocol in Relation to Clinical Outcomes and Management.
    Hakkers CS; Kraaijenhof JM; van Oers-Hazelzet EB; Visser-Meily AJMA; Hoepelman AIM; Arends JE; Barth RE
    AIDS Patient Care STDS; 2017 Sep; 31(9):363-369. PubMed ID: 28783374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning.
    Fazeli PL; Casaletto KB; Paolillo E; Moore RC; Moore DJ; The Hnrp Group
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):842-853. PubMed ID: 28122474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple screening for neurocognitive impairment in routine HIV outpatient care: is it deliverable?
    Parry S; Zetler S; Kentridge A; Petrak J; Barber T
    AIDS Care; 2017 Oct; 29(10):1275-1279. PubMed ID: 28292203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impairment and neurocognitive profiles among people living with HIV and HIV-negative individuals older over 50 years: a comparison of IHDS, MMSE and MoCA.
    Chen P; Xin X; Xiao S; Liu H; Liu X; He N; Ding Y
    J Neurovirol; 2024 Apr; 30(2):103-114. PubMed ID: 38709469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validity of the Montreal Cognitive Assessment and the HIV Dementia Scale in the assessment of cognitive impairment in HIV-1 infected patients.
    Janssen MA; Bosch M; Koopmans PP; Kessels RP
    J Neurovirol; 2015 Aug; 21(4):383-90. PubMed ID: 25678141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Montreal Cognitive Assessment-Basic (MoCA-B) is not a reliable screening tool for cognitive decline in HIV patients receiving combination antiretroviral therapy in rural South Africa.
    Hakkers CS; Beunders AJM; Ensing MHM; Barth RE; Boelema S; Devillé WLJ; Tempelman HA; Coutinho RA; Hoepelman AIM; Arends JE; van Zandvoort MJE
    Int J Infect Dis; 2018 Feb; 67():36-40. PubMed ID: 29183843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional deficits and other psychiatric associations with abnormal scores on the Montreal Cognitive Assessment (MoCA) in older HIV-infected patients.
    Bourgeois JA; John M; Zepf R; Greene M; Frankel S; Hessol NA
    Int Psychogeriatr; 2020 Jan; 32(1):105-118. PubMed ID: 31014404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?
    Metral M; Nadin I; Locatelli I; Tarr PE; Calmy A; Kovari H; Brugger P; Cusini A; Gutbrod K; Schmid P; Schwind M; Kunze U; Di Benedetto C; Pignatti R; Du Pasquier R; Darling K; Cavassini M;
    HIV Med; 2020 May; 21(5):342-348. PubMed ID: 31883203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive screening in treatment-naïve HIV-infected individuals in Hong Kong - a single center study.
    Chan FCC; Chan P; Chan I; Chan A; Tang THC; Lam W; Fong WC; Lee MP; Li P; Chan GHF
    BMC Infect Dis; 2019 Feb; 19(1):156. PubMed ID: 30760220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low levels of neurocognitive impairment detected in screening HIV-infected men who have sex with men: The MSM Neurocog Study.
    Barber TJ; Bansi L; Pozniak A; Asboe D; Nelson M; Moyle G; Davies N; Margetts A; Ratcliffe D; Catalan J; Boffito M; Gazzard B
    Int J STD AIDS; 2017 Jun; 28(7):715-722. PubMed ID: 27510645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil.
    Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP
    AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive evaluation using the International HIV Dementia Scale (IHDS) and Montreal Cognitive Assessment Test (MoCA) in an HIV-2 population.
    Almeida F; Macedo A; Trigo D; Abreu M; Guimarães M; Luís N; Pinho R; Tavares R
    HIV Med; 2021 Mar; 22(3):212-217. PubMed ID: 33012065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for HIV-Associated Neurocognitive Impairment: Relevance of Psychological Factors and Era of Commencement of Antiretroviral Therapy.
    Herrmann S; McKinnon E; Skinner M; Duracinsky M; Chaney R; Locke V; Mastaglia F
    J Assoc Nurses AIDS Care; 2019; 30(1):42-50. PubMed ID: 30586348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE).
    Milanini B; Ciccarelli N; Fabbiani M; Baldonero E; Limiti S; Gagliardini R; Borghetti A; D'Avino A; Mondi A; Colafigli M; Cauda R; Di Giambenedetto S
    Clin Neuropsychol; 2016; 30(sup1):1457-1468. PubMed ID: 27180611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders.
    Costaggiu D; Pinna E; Serchisu L; Barcellona D; Piano P; Ortu F; Marongiu F; Mandas A
    AIDS Care; 2021 Mar; 33(3):357-363. PubMed ID: 32183560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are MMSE and HDS-R neuropsychological tests adequate for screening HIV-associated neurocognitive disorders?
    Nakazato A; Tominaga D; Tasato D; Miyagi K; Nakamura H; Haranaga S; Higa F; Tateyama M; Fujita J
    J Infect Chemother; 2014 Mar; 20(3):217-9. PubMed ID: 24462448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Montreal Cognitive Assessment: A Pilot Study of a Brief Screening Tool for Mild and Moderate Cognitive Impairment in HIV-Positive Veterans.
    Chartier M; Crouch PC; Tullis V; Catella S; Frawley E; Filanosky C; Carmody T; McQuaid J; Lampiris H; Wong JK
    J Int Assoc Provid AIDS Care; 2015; 14(3):197-201. PubMed ID: 25487428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-related neurocognitive impairment screening: the patient's perspective on its utility and psychological impact.
    Nightingale A; Ratcliffe D; Leonidou L; Margetts A; Asboe D; Gazzard B; Catalan J; Barber TJ
    AIDS Care; 2014; 26(8):1036-41. PubMed ID: 24625218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Montreal Cognitive Assessment Performance in HIV/AIDS: Impact of Systemic Factors.
    Koenig N; Fujiwara E; Gill MJ; Power C
    Can J Neurol Sci; 2016 Jan; 43(1):157-62. PubMed ID: 26635008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired Neurocognitive Performance and Mortality in HIV: Assessing the Prognostic Value of the HIV-Dementia Scale.
    Banerjee N; McIntosh RC; Ironson G
    AIDS Behav; 2019 Dec; 23(12):3482-3492. PubMed ID: 30820848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.